Solange Peters, MD, PhD, Discusses Key Abstracts Presented at the 2021 ESMO Congress

Video
Conference|European Society for Medical Oncology Congress (ESMO)

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

CancerNetwork spoke with Solange Peters, MD, PhD, head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire Vaudois and president of the European Society for Medical Oncology (ESMO), about key abstracts that read out at the 2021 ESMO Congress. Several of the trials, including the phase 3 DESTINY-Breast03 trial (NCT03529110), examining the use of fam-trastuzumab deruxtecan-nxki (Enhertu) vs trastuzumab emtansine (Kadcyla; T-DM1) in patients with HER2-positive metastatic breast cancer, as well as the phase 3 KEYNOTE-826 trial (NCT03635567), which assessed pembrolizumab (Keytruda) plus chemotherapy compared with chemotherapy alone in metastatic cervical cancer.

Transcription:

So, there are 3 Presidential [Symposia], which encompass the definition of practice changing abstracts… We have trastuzumab deruxtecan vs TDM-1 in HER2-positive metastatic breast cancer,1 [which is an] amazing trial. We have pembrolizumab plus chemotherapy vs chemotherapy for metastatic cervical cancer2, which is not-so-often observed in big sessions [and is] an amazing trial, too. Very important is the extension of the pembrolizumab indication in the [adjuvant] melanoma setting3, [which was] also presented today.

Tomorrow, we have also 2 breaking news [presentations] in castration-sensitive prostate cancer—one in early and 1 in late disease [with] these new combinations of drugs.4 We have the KRAS inhibitor adagrasib plus cetuximab (Erbitux), which also [has] amazing data in colorectal cancer.5 We [also] have [nivolumab]/chemotherapy in gastric cancer.6

References

  1. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at: European Society for Medical Oncology Annual Congress 2021; September 16-21, 2021; virtual. Abstract LBA1.
  2. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA2_PR.
  3. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase 3 trial. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA3_PR.
  4. Attard G, Brown L, Clarke N, et al. Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021; virtual. Abstract LBA4.
  5. Mirati Therapeutics announces positive phase 2 topline results for investigational adagrasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer. News release. Mirati Therapeutics, Inc. September 20, 2021. Accessed September 20, 2021. https://bit.ly/3zoRpLZ
  6. Janjigian YY, Ajani JA, Moehler M, et al. Nivolumab (nivo) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemo as first-line (1L) Treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. LBA7.
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
Related Content
T-DXd Sequencing and Treatment Options in the Tumor-Agnostic Setting

T-DXd Sequencing and Treatment Options in the Tumor-Agnostic Setting

ONCOLOGY Staff
November 15th 2024
Article

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Denileukin Diftitox Combo Shows Promising ORR and CBR in Solid Tumors

Tim Cortese
November 14th 2024
Article

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study.

Pimicotinib Significantly Improves Responses Vs Placebo in TGCT

Russ Conroy
November 13th 2024
Article

Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study.

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.

THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer

Kyle Doherty
November 11th 2024
Article

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.